ACADIA Pharmaceuticals Inc. ACAD
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About ACAD
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
ACADIA Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders and rare diseases. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with an emphasis on neurological and neuropsychiatric conditions that have limited treatment options. Its revenue is primarily derived from commercialized prescription therapies and related licensing activities.
The company’s principal products include NUPLAZID (pimavanserin), approved for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), approved for Rett syndrome. ACADIA has also maintained clinical development programs targeting additional neurological and psychiatric indications. The company positions itself within highly specialized therapeutic markets where unmet medical need, orphan-drug opportunities, and physician specialization can support differentiated pricing and market access. Founded in 1993 and headquartered in San Diego, California, ACADIA evolved from an early-stage neuroscience research company into a commercial-stage biopharmaceutical business following the U.S. regulatory approval and launch of NUPLAZID.
Business Operations
ACADIA generates most of its revenue from product sales in the United States, particularly through commercialization of NUPLAZID and DAYBUE. The company’s operations include drug discovery, clinical development, regulatory affairs, manufacturing oversight, medical affairs, and specialty pharmaceutical commercialization. ACADIA relies on a combination of internal development capabilities and external contract manufacturing and research organizations to support production and clinical programs. The company’s commercial strategy focuses on neurologists, movement disorder specialists, pediatric specialists, institutional care providers, and rare disease treatment centers.
The company operates primarily in the United States but has pursued selective international activities through partnerships and regulatory initiatives. ACADIA has maintained collaborations with third-party manufacturers and development partners to support supply chain operations and clinical advancement. Historically, the company expanded its portfolio through acquisitions and licensing transactions, including the acquisition of Cerecor Inc.’s trofinetide program, which became the basis for DAYBUE. ACADIA’s pipeline and commercial infrastructure are concentrated in CNS and rare neurological disorders, where the company seeks to leverage specialized expertise and established physician relationships.
Strategic Position & Investments
ACADIA’s strategic direction centers on expanding its neuroscience and rare disease portfolio through internal research, lifecycle management of approved products, and targeted business development transactions. The company has invested significantly in clinical trials evaluating pimavanserin across multiple neuropsychiatric indications, although not all programs have achieved regulatory approval or successful trial outcomes. The commercialization of DAYBUE represented a major strategic expansion into rare pediatric neurological disorders and diversified the company beyond Parkinson’s disease psychosis.
The company has pursued investments in clinical-stage assets and licensing opportunities intended to strengthen its long-term pipeline. ACADIA has also focused on strengthening its commercial infrastructure, medical affairs capabilities, and patient support programs to support specialty product adoption. Its strategic positioning is tied to expertise in CNS drug development, orphan-drug commercialization, and regulatory pathways for neurological disorders. Public filings and company disclosures indicate ongoing interest in expanding both early-stage and late-stage neuroscience assets, though some future development priorities remain subject to clinical and regulatory outcomes.
Geographic Footprint
ACADIA is headquartered in San Diego, California, and maintains operations primarily in the United States, which represents its largest commercial market. The company’s products are marketed principally through U.S.-focused specialty pharmaceutical infrastructure, including sales, reimbursement support, and patient access programs. While ACADIA has historically explored broader international opportunities, its direct commercial presence outside the United States has remained comparatively limited relative to larger multinational pharmaceutical companies.
The company’s operational influence extends internationally through clinical trial activities, supply chain partnerships, and regulatory engagement in selected global markets. ACADIA has utilized international contract manufacturers, research organizations, and development collaborators to support drug production and global clinical studies. Its market presence has been strongest in North America, though the company has evaluated opportunities in additional regions through partnerships and strategic planning initiatives.
Leadership & Governance
ACADIA’s leadership team oversees a strategy focused on neuroscience innovation, specialty commercialization, and expansion within rare diseases. Governance is led by a board of directors and executive management team with backgrounds in biotechnology, pharmaceuticals, commercialization, and clinical development. The company’s strategic philosophy has emphasized addressing underserved neurological conditions while balancing commercial execution with continued pipeline investment.
Key executives include:
- Catherine Owen Adams – Chief Executive Officer
- Mark C. Schneyer – Executive Vice President, Chief Financial Officer
- Elizabeth A. H.Z. Thompson – Executive Vice President, Research and Development
- Thomas H. Aasen – Executive Vice President, General Counsel and Secretary
- Brian S. Fiske – Executive Vice President, Chief Commercial Officer
ACADIA was founded by scientists and biotechnology entrepreneurs focused on CNS drug discovery. Leadership communications in public filings and investor materials have consistently emphasized long-term neuroscience specialization, disciplined portfolio development, and expansion through both internal innovation and external strategic transactions.